EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Peripherin is a biomarker of axonal damage in Guillain-Barré syndrome: a pathophysiological annotation

José Berciano

Brain · 2024

DOI: 10.1093/brain/awad277 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Brain, 2024. Verfasst von José Berciano. Beteiligte Einrichtung: University of Cantabria, University Hospital 'Marqués de Valdecilla (IDIVAL)' and 'Centro de Investigación Biomédica en Red de Enfermedades Neurodege…. Hauptthemen laut MEDLINE: Guillain-Barre Syndrome. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

I read with great interest the paper by Keddie and colleagues,1 who report that serum peripherin is a promising, new and specific biomarker of acute axonal damage in several disorders of the peripheral nervous system. I wish to comment on just their findings in Guillain-Barré syndrome (GBS). The series comprises 45 GBS patients, with clinical data available for 25 of them.1 Based on nerve conduction studies, performed in 21 cases, the syndrome was categorized as demyelinating in 14 (67%), primarily axonal in five (23%) and mixed in two (10%). Serial peripherin levels conformed to distinct longitudinal patterns, the majority of them displaying a rise-and-fall, with the highest value either at the first assessment or within the first week after onset, namely in the period arbitrarily assigned for early GBS.2 Just five (20%) patients exhibited peripherin levels below the lower limit of detection. The paper states that ‘We have generated a highly sensitive Simoa-based immunoassay which measures serum peripherin as a biomarker of peripheral nerve axonal injury. Peripherin levels were raised significantly in patients with GBS … Recent ideas of GBS being a spectrum of nodo-paranopathy with varying degrees of paranodal and axonal damage determining the electrophysiological phenotype may be supported by these data. Although almost all GBS cases in the UK are “demyelinating”, the data here suggest peripherin consistently raises, indicating axonal damage in most cases’.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Guillain-Barre SyndromeHumansPeripherinsBiomarkersAxonsIntermediate Filaments

Substanzen

PeripherinsBiomarkers

Autor:innen und Institutionen

  • University of Cantabria, University Hospital 'Marqués de Valdecilla (IDIVAL)' and 'Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED)', 39008 Santander, Spain.

Zitieren

APA

Berciano, J. (2024). Peripherin is a biomarker of axonal damage in Guillain-Barré syndrome: a pathophysiological annotation. Brain. https://doi.org/10.1093/brain/awad277

Vancouver

Berciano J. Peripherin is a biomarker of axonal damage in Guillain-Barré syndrome: a pathophysiological annotation. Brain. 2024. doi:10.1093/brain/awad277

BibTeX
@article{Berciano2024,
  author = {Berciano, José},
  title = {Peripherin is a biomarker of axonal damage in Guillain-Barré syndrome: a pathophysiological annotation},
  journal = {Brain},
  year = {2024},
  doi = {10.1093/brain/awad277}
}
Kostenlos starten →